287 related articles for article (PubMed ID: 23555877)
1. Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile.
Scorzoni L; de Lucas MP; Mesa-Arango AC; Fusco-Almeida AM; Lozano E; Cuenca-Estrella M; Mendes-Giannini MJ; Zaragoza O
PLoS One; 2013; 8(3):e60047. PubMed ID: 23555877
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model.
Ghannoum MA; Okogbule-Wonodi I; Bhat N; Sanati H
J Chemother; 1999 Feb; 11(1):34-9. PubMed ID: 10078778
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Galleria mellonella as an alternative in vivo model to study implant-associated fungal infections.
Mannala GK; Rupp M; Walter N; Scholz KJ; Simon M; Riool M; Alt V
J Orthop Res; 2023 Nov; 41(11):2547-2559. PubMed ID: 37080929
[TBL] [Abstract][Full Text] [Related]
5. Antifungal resistance: the clinical front.
Perfect JR
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):15-22. PubMed ID: 15682590
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.
Majithiya J; Sharp A; Parmar A; Denning DW; Warn PA
J Antimicrob Chemother; 2009 Jan; 63(1):161-6. PubMed ID: 19008255
[TBL] [Abstract][Full Text] [Related]
7. Virulence of Candida haemulonii complex in Galleria mellonella and efficacy of classical antifungal drugs: a comparative study with other clinically relevant non-albicans Candida species.
Silva LN; Campos-Silva R; Ramos LS; Trentin DS; Macedo AJ; Branquinha MH; Santos ALS
FEMS Yeast Res; 2018 Nov; 18(7):. PubMed ID: 30052907
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of triazoles in a murine disseminated infection by Candida krusei.
Mariné M; Pastor FJ; Serena C; Guarro J
Antimicrob Agents Chemother; 2009 Aug; 53(8):3585-8. PubMed ID: 19470509
[TBL] [Abstract][Full Text] [Related]
9. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole and fluconazole susceptibility of Candida isolates.
Pelletier R; Loranger L; Marcotte H; DE Carolis E
J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
[TBL] [Abstract][Full Text] [Related]
11. Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Manfredi R; Sabbatani S
Scand J Infect Dis; 2006; 38(10):950-1. PubMed ID: 17008248
[TBL] [Abstract][Full Text] [Related]
12. The non-mammalian host Galleria mellonella can be used to study the virulence of the fungal pathogen Candida tropicalis and the efficacy of antifungal drugs during infection by this pathogenic yeast.
Mesa-Arango AC; Forastiero A; Bernal-Martínez L; Cuenca-Estrella M; Mellado E; Zaragoza O
Med Mycol; 2013 Jul; 51(5):461-72. PubMed ID: 23170962
[TBL] [Abstract][Full Text] [Related]
13. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
14. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
Sanati H; Belanger P; Fratti R; Ghannoum M
Antimicrob Agents Chemother; 1997 Nov; 41(11):2492-6. PubMed ID: 9371355
[TBL] [Abstract][Full Text] [Related]
15. Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns.
Pemán J; Jarque I; Bosch M; Cantón E; Salavert M; de Llanos R; Molina A
J Clin Microbiol; 2006 May; 44(5):1912-4. PubMed ID: 16672439
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibilities of Candida species isolated from urine culture.
Toka Özer T; Durmaz S; Yula E
J Infect Chemother; 2016 Sep; 22(9):629-32. PubMed ID: 27452427
[TBL] [Abstract][Full Text] [Related]
17. Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.
Lee JK; Peters D; Obias AA; Noskin GA; Peterson LR
Int J Antimicrob Agents; 2000 Nov; 16(3):205-9. PubMed ID: 11091037
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of polyunsaturated fatty acids alone or in combination with fluconazole on Candida krusei biofilms in vitro and in Caenorhabditis elegans.
Jamiu AT; Albertyn J; Sebolai O; Gcilitshana O; Pohl CH
Med Mycol; 2021 Dec; 59(12):1225-1237. PubMed ID: 34558629
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
20. SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Karyotakis NC; Dignani MC; Anaissie EJ
Antimicrob Agents Chemother; 1995 Mar; 39(3):775-7. PubMed ID: 7793892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
